Last reviewed · How we verify
SB414 6%
At a glance
| Generic name | SB414 6% |
|---|---|
| Also known as | NVN1000 |
| Sponsor | Novan, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1b Study Assessing the PK, PD, Safety & Tolerability of SB414 in Atopic Dermatitis (PHASE1)
- A Study Assessing the PK, PD, Safety, and Tolerability of SB414 in Psoriasis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SB414 6% CI brief — competitive landscape report
- SB414 6% updates RSS · CI watch RSS
- Novan, Inc. portfolio CI